Efficacy of Butyrate to Inhibit Colonic Cancer Cell Growth Is Cell Type-Specific and Apoptosis-Dependent.

Increasing dietary fiber consumption is linked to lower colon cancer incidence, and this anticancer effect is tied to elevated levels of short-chain fatty acids (e.g., butyrate) because of the fermentation of fiber by colonic bacteria. While butyrate inhibits cancer cell proliferation, the impact on cancer cell type remains largely unknown. To test the hypothesis that butyrate displays different inhibitory potentials due to cancer cell type, we determined half-maximal inhibitory concentrations (IC50) of butyrate in HCT116, HT-29, and Caco-2 human colon cancer cell proliferation at 24, 48, and 72 h. The IC50 (mM) butyrate concentrations of HCT116, HT-29, and Caco-2 cells were [24 h, 1.14; 48 h, 0.83; 72 h, 0.86], [24 h, N/D; 48 h, 2.42; 72 h, 2.15], and [24 h, N/D; 48 h, N/D; 72 h, 2.15], respectively. At the molecular level, phosphorylated ERK1/2 and c-Myc survival signals were decreased by (>30%) in HCT116, HT-29, and Caco-2 cells treated with 4 mM butyrate. Conversely, butyrate displayed a stronger potential (>1-fold) for inducing apoptosis and nuclear p21 tumor suppressor in HCT116 cells compared to HT-29 and Caco-2 cells. Moreover, survival analysis demonstrated that a cohort with high p21 gene expression in their colon tissue significantly increased survival time compared to a low-p21-expression cohort of colon cancer patients. Collectively, the inhibitory efficacy of butyrate is cell type-specific and apoptosis-dependent.

Determination of selenium bioavailability from wheat mill fractions in rats by using the slope-ratio assay and a modified torula yeast-based diet.

Selenium is an essential mineral micronutrient for animals, and significant evidence supports an association between supranutritional Se intake and a reduction in the incidence of some forms of cancer. Thus, supplemental Se intake may provide an avenue for reducing cancer incidence. However, an important issue to consider is the form of Se that should be provided in such a supplement, because the bioavailability and bioactivity of Se can vary dramatically depending on the chemical form in which it is delivered. Because wheat products are the largest source of Se in U.S. diets, the absorption of Se was evaluated in different fractions of milled wheat that exhibits very high Se levels, owing to its production on naturally Se-rich soils. An experiment was conducted to determine the bioavailability of Se from three milled fractions of high-Se wheat. The method used was the slope-ratio assay, which measures the ability of Se from the wheat fractions to regenerate Se-dependent enzyme activities and tissue Se concentrations in Se-deficient rats. The responses generated from wheat Se were compared to a standard response curve generated by feeding graded amounts of Se as sodium selenite (Na2SeO3; NaSelenite) or selenomethionine (SeMet) in an AIN-93G-Torula yeast-based diet. Results showed that Se from wheat flour ( approximately 75% extraction) was nearly 100% available by a number of measures including plasma, liver, kidney, and muscle Se concentrations and liver and erythrocyte Se-dependent enzyme activities when compared with similar measures in rats fed NaSelenite or SeMet. However, on the basis of similar criteria, Se from wheat shorts was only about 85% available and that from wheat bran was about 60% available for absorption. These results indicate that high-Se wheat products, mainly those made from refined flour alone, might be particularly well suited for use as dietary Se supplements.

Selenium bioavailability from buckwheat bran in rats fed a modified AIN-93G torula yeast-based diet.

Selenium (Se) is an essential nutrient for humans and animals. The Se RDA for adult humans is 55 mug/d; however, dietary amounts as high as 200 mug/d in the highly available form of selenomethionine in yeast were shown to reduce the incidence of certain cancers. A number of natural foods contain relatively high amounts of Se; for the most part, however, the availability of food Se for absorption and utilization is unknown. This experiment was conducted to determine the bioavailability of Se from a high-protein, high-fiber bran-isolate of buckwheat groats that contains Se. The method used was based on the ability of Se from buckwheat bran to restore Se-dependent enzyme activities and tissue Se concentrations in Se-deficient rats. The responses produced from buckwheat bran Se were compared with a standard response curve generated by feeding graded amounts of Se as sodium selenite (Na(2)SeO(3); Na selenite) or selenomethionine (SeMet) in a newly reformulated AIN-93G-Torula yeast diet with a more balanced nutrient composition than older diets of this nature. Relative bioavailability was determined by using the slope-ratio assay method for enzyme data, or the parallel lines assay method for tissue Se concentration data. Results showed that Se availability from buckwheat bran based on the restoration of plasma Se was 70-80% as high as Na selenite or SeMet. However, when based on the restoration of muscle Se, buckwheat bran was 90% as high as Na selenite, but only 60% as high as SeMet. When using the ability of dietary Se to restore whole blood and liver glutathione peroxidase activity, buckwheat bran Se was 75-80% as high as Na selenite or SeMet. However, for the restoration of liver thioredoxin reductase, buckwheat bran Se was only 40% as high as Na selenite and 70% as high as SeMet. The relative bioavailability of Se from buckwheat bran with all variables considered was approximately 73% whether measured against Na selenite or SeMet. Although some variables indicated low bioavailability of Se from buckwheat bran, other factors such as Se speciation in the bran, digestibility of the bran, the cooking process, and combinations with other foods in the diet should be considered and analyzed before firm conclusions can be reached.